RemeGen (HKG:9995, SHA:688331) expects to record a net loss attributable to owners of the parent company of 1.47 billion yuan for 2024, 3% narrower than 1.51 billion yuan logged for the prior year, a Thursday Hong Kong bourse filing said.
The biopharmaceutical company attributed the reduction in expected net attributable loss to the rapid increase in sales revenue from its drugs, telitacicept and disitamab vedotin, in the market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.